STUDY DESIGN: Single cohort study of patients undergoing revision fusion for lumbar pseudoarthrosis. OBJECTIVE: To assess the 2-year comprehensive costs of revision arthrodesis for lumbar pseudoarthrosis at our institution and determine the associated cost per quality-adjusted life year (QALY) gained in this patient population. SUMMARY OF BACKGROUND DATA: The proportion of lumbar spine operations involving a fusion procedure has increased over the past 2 decades. Similarly, there has been a corresponding increase in the incidence and prevalence of pseudoarthrosis. However, the cost-effectiveness of revision surgery for pseudoarthrosis-associated back pain has yet to be examined. METHODS: Forty-seven patients undergoing revision instrumented arthrodesis for pseudoarthrosis-associated back pain were included. Two-year total back-related medical resource utilization, missed work, and health-state values (QALYs, calculated from EuroQuol 5D with US valuation) were assessed. Two-year resource use was multiplied by unit costs based on Medicare national allowable payment amounts (direct cost) and patient and care-giver work-day losses were multiplied by the self-reported gross-of-tax wage rate (indirect cost). The mean total 2-year cost per QALY gained after revision surgery was assessed. RESULTS: The mean (±SD) duration of time between prior fusion and development of symptomatic pseudoarthrosis was 2.69±3.09 years. None of the patients developed symptomatic pseudoarthrosis after 2 years of revision surgery. A mean cumulative 2-year gain of 0.35 QALYs was reported. The mean (±SD) total 2-year cost of revision fusion was $41,631±$9691 (surgery cost: $23,865±$270; outpatient resource utilization cost: $4885±$2301; indirect cost: $12,879±$8171). Revision instrumented arthrodesis was associated with a mean 2-year cost per QALY gained of $118,945. CONCLUSIONS: Revision arthrodesis was associated with improved 2-year quality of life in patients with pseudoarthrosis-related back pain. Nevertheless, in our experience revision surgery was shown to be marginally cost-effective at $118,945 per QALY gained.
STUDY DESIGN: Single cohort study of patients undergoing revision fusion for lumbar pseudoarthrosis. OBJECTIVE: To assess the 2-year comprehensive costs of revision arthrodesis for lumbar pseudoarthrosis at our institution and determine the associated cost per quality-adjusted life year (QALY) gained in this patient population. SUMMARY OF BACKGROUND DATA: The proportion of lumbar spine operations involving a fusion procedure has increased over the past 2 decades. Similarly, there has been a corresponding increase in the incidence and prevalence of pseudoarthrosis. However, the cost-effectiveness of revision surgery for pseudoarthrosis-associated back pain has yet to be examined. METHODS: Forty-seven patients undergoing revision instrumented arthrodesis for pseudoarthrosis-associated back pain were included. Two-year total back-related medical resource utilization, missed work, and health-state values (QALYs, calculated from EuroQuol 5D with US valuation) were assessed. Two-year resource use was multiplied by unit costs based on Medicare national allowable payment amounts (direct cost) and patient and care-giver work-day losses were multiplied by the self-reported gross-of-tax wage rate (indirect cost). The mean total 2-year cost per QALY gained after revision surgery was assessed. RESULTS: The mean (±SD) duration of time between prior fusion and development of symptomatic pseudoarthrosis was 2.69±3.09 years. None of the patients developed symptomatic pseudoarthrosis after 2 years of revision surgery. A mean cumulative 2-year gain of 0.35 QALYs was reported. The mean (±SD) total 2-year cost of revision fusion was $41,631±$9691 (surgery cost: $23,865±$270; outpatient resource utilization cost: $4885±$2301; indirect cost: $12,879±$8171). Revision instrumented arthrodesis was associated with a mean 2-year cost per QALY gained of $118,945. CONCLUSIONS: Revision arthrodesis was associated with improved 2-year quality of life in patients with pseudoarthrosis-related back pain. Nevertheless, in our experience revision surgery was shown to be marginally cost-effective at $118,945 per QALY gained.
Authors: Jason I Liounakos; Vignessh Kumar; Aria Jamshidi; Zmira Silman; Christopher R Good; Samuel R Schroerlucke; Andrew Cannestra; Victor Hsu; Jae Lim; Faissal Zahrawi; Pedro M Ramirez; Thomas M Sweeney; Michael Y Wang Journal: J Robot Surg Date: 2021-01-01
Authors: Zhao Lang; Jing-Sheng Li; Felix Yang; Yan Yu; Kamran Khan; Louis G Jenis; Thomas D Cha; James D Kang; Guoan Li Journal: Eur Spine J Date: 2018-06-28 Impact factor: 3.134
Authors: Nikhil R Nayak; James H Stephen; Matthew A Piazza; Adetokunbo A Obayemi; Sherman C Stein; Neil R Malhotra Journal: Global Spine J Date: 2018-07-29
Authors: J Alex Sielatycki; Masanori Saito; Masato Yuasa; Stephanie N Moore-Lotridge; Sasidhar Uppuganti; Juan M Colazo; Alexander A Hysong; J Patton Robinette; Atsushi Okawa; Toshitaka Yoshii; Herbert S Schwartz; Jeffry S Nyman; Jonathan G Schoenecker Journal: JOR Spine Date: 2018-03-23
Authors: John Rodriguez-Feo; Lorenzo Fernandes; Anuj Patel; Thanh Doan; Scott D Boden; Hicham Drissi; Steven M Presciutti Journal: JOR Spine Date: 2020-06-25
Authors: Kai-Uwe Lewandrowski; Ivo Abraham; Jorge Felipe Ramírez León; Albert E Telfeian; Morgan P Lorio; Stefan Hellinger; Martin Knight; Paulo Sérgio Teixeira De Carvalho; Max Rogério Freitas Ramos; Álvaro Dowling; Manuel Rodriguez Garcia; Fauziyya Muhammad; Namath Hussain; Vicky Yamamoto; Babak Kateb; Anthony Yeung Journal: J Pers Med Date: 2022-06-29